Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer
So Mee KwoniD, Anuradha BudhuiD, Hyun Goo WooiD, Jittiporn ChaisaingmongkoliD, Hien Thanh DangiD, Marshonna ForguesiD, Curtis C. HarrisiD, Gao ZhangiD, Noam AuslanderiD, Eytan RuppiniD, Chulabhorn MahidoliD, Mathuros RuchirawatiD, Xin Wei WangiD
Abstract
BackgroundChronic inflammation and chromosome aneuploidy are major traits of primary liver cancer (PLC), which represent the second most common cause of cancer related death worldwide. Increased cancer fitness and aggressiveness of PLC may be achieved by enhancing tumoral genomic complexity that alters tumor biology.\n\nMethodHere, we developed a scoring method, namely functional genomic complexity (FGC), to determine the degree of molecular heterogeneity among 580 liver tumors with diverse ethnicities and etiologies by assessing integrated genomic and transcriptomic data.\n\nResultsWe found that tumors with higher FGC scores are associated with chromosome instability and TP53 mutations, and a worse prognosis, while tumors with lower FGC scores have elevated infiltrating lymphocytes and a better prognosis. These results indicate that FGC scores may serve as a surrogate to define genomic heterogeneity of PLC linked to chromosomal instability and evasion of immune surveillance.\n\nConclusionOur findings demonstrate an ability to define genomic heterogeneity and corresponding tumor biology of liver cancer based only on bulk genomic and transcriptomic data. Our data also provide a rationale for applying this approach to survey liver tumor immunity and to stratify patients for immune-based therapy.\n\nSTATEMENT OF SIGNIFICANCEGenomic heterogeneity contributes to therapeutic failure and poor outcome in patients with liver cancer and poses a challenge in defining targeted therapy. Our findings demonstrate an ability to define genomic heterogeneity and corresponding tumor biology of liver cancer based only on bulk genomic and transcriptomic data. Our data also provide a rationale for applying this approach to survey liver tumor immunity and to stratify patients for immune-based therapy. \\body
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 18
- FWCI
- 0.87
- Field percentile
- top 35%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The immune and genetic heterogeneity of Hepatocellular Carcinoma, with a focus on multifocal disease
Adam C. Connor, Leon Chang, … Adel Samson·CancersPeer-reviewed·Sep 22, 2026
- Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer
Kyungsik Ha, Masashi Fujita, … Hwajin Lee·HeliyonPeer-reviewed·Feb 1, 2020
- Novel insights into the molecular heterogeneity of hepatocellularcarcinoma
Juan Jovel, Zhen Lin, … Andrew L. Mason·bioRxiv·Jan 19, 2017
- Identification of Proliferation-Specific Dependencies for Therapeutic Targeting of Liver Cancer
M. Castoldi·bioRxiv·Jul 9, 2026
- MS.liverK: an R package for transcriptome-based computation of molecular subtypes and functional signatures in liver cancer
Florent Petitprez, Léa Meunier, … Aurélien de Reyniès·bioRxiv·Feb 7, 2019
- Higher basal tumor immune activity coupled with a systemic immune response improves liver cancer outcomes
Ghazal Alipour Talesh, Daniele Vitale, … Saeed Esmaili·bioRxiv·Apr 16, 2022